haidong cai

Dr. haidong cai


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

11 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HZHui Zheng
Hui Zheng
MZMengyu Zhang
Mengyu Zhang
DGDingwei Gao
Dingwei Gao
XZXiaoying Zhang
Xiaoying Zhang
HChaidong cai
haidong cai
ZLzhongwei Lv
zhongwei Lv
PLA2R1 is a novel gene that is aberrantly expressed in a variety of malignancies. However, the role and mechanism of PLA2R1 in thyroid cancer has not been elucidated. We aimed to uncover the underlying mechanism of PLA2R1 in thyroid cancer. We collected 115 clinical specimens, including 54 tumor tissues and 61 para-cancerous tissues, who underwent surgical treatment at Shanghai Tenth Hospital. Immunohistochemical staining was used to evaluate PLA2R1 expression in differentiated thyroid cancer (DTC) tissues. The thyroid cancer cell lines 8505c and FTC133 transfected with PLA2R1 overexpression or knockdown plasmids were used for CCK8 assays and a wound healing assay. Next, we conducted coimmunoprecipitation (Co-IP) experiments and western blotting to explore the underlying mechanism of PLA2R1 in regulating the growth of thyroid cancer. We discovered that the expression of PLA2R1 was lower in the tumor tissues than in para-cancerous tissues (χ2 = 37.0, p < 0.01). The overexpression of PLA2R1 significantly suppressed thyroid cancer cell proliferation and migration, and both of these effects were partially attenuated by the knockdown of PLA2R1. Furthermore, the in vivo growth of DTC could be alleviated by the knockdown of PLA2R1. The mechanistic study revealed that PLA2R1 competed with FN1 for binding to ITGB1, inhibiting the FAK axis and epithelial-mesenchymal transition (EMT). We speculate that PLA2R1 might be a promising marker and a novel therapeutic target for thyroid cancer.

22 May 2023 in Endocrine Practice
Verified
Journal Article
Closed access
WYWanwan Yi
Wanwan Yi
MZMengyu Zhang
Mengyu Zhang
XYXueYu Yuan
XueYu Yuan
LSLishuai Shi
Lishuai Shi
XYXie Yuan
Xie Yuan
ZLzhongwei Lv
zhongwei Lv

7 March 2025 in The FASEB Journal
Verified
Journal Article
Open access
RWRu Wang
Ru Wang
XYXiaqing Yu
Xiaqing Yu
HChaidong cai
haidong cai
GLGanghua Lu
Ganghua Lu
DGDingwei Gao
Dingwei Gao
ZLzhongwei Lv
zhongwei Lv
Gut microbiota has a close connection to different thyroid disorders, yet research on its links to subclinical hypothyroidism (SCH) remains limited and insufficient. In this study, we explored the potential relationship between the gut microbiota and SCH, as well as dyslipidemia in SCH mice. The SCH mouse model was induced using methimazole. The composition of the gut microbiota from mice was then analyzed through 16S rRNA gene sequencing technology. An antibiotic disruption experiment was used to assess how gut microbiota imbalance impacts thyroid function. The SCH mouse models were constructed and accompanied by significant dyslipidemia. The results revealed no significant differences in the Firmicutes to Bacteroidota ratio or α‐diversity in gut microbiota from SCH and control mice, and in β‐diversity, there was a noticeable but small difference between the groups. 14 differential genera between the two groups identified through LEfSe analysis were significantly correlated with serum lipid levels. Furthermore, the results of the antibiotic disruption experiment demonstrated that gut microbiota imbalance exacerbated the hypothyroidism in mice. The present results suggest that subclinical hypothyroidism has not yet caused significant changes in gut microbiota homeostasis, but gut microbiota plays an important role in regulating thyroid function and is closely associated with dyslipidemia in SCH. This study could help understand the relationship between gut microbiota and SCH, and offer new perspectives on dyslipidemia management in SCH.

3 November 2026
Verified
Other
Open access
TQTingting Qiao
Tingting Qiao
SWShaoping Wang
Shaoping Wang
CWChenXing Wang
ChenXing Wang
LHLei Hu
Lei Hu
HChaidong cai
haidong cai
ZLZhongwei Lv
Zhongwei Lv
Supplementary Figure 9 depicts flow cytometric evaluations showing increased proportions of total CD45+ and CD3+ cells in H22 tumors following combination therapy.

3 November 2026
Verified
Other
Open access
TQTingting Qiao
Tingting Qiao
SWShaoping Wang
Shaoping Wang
CWChenXing Wang
ChenXing Wang
LHLei Hu
Lei Hu
HChaidong cai
haidong cai
ZLZhongwei Lv
Zhongwei Lv
Supplementary Figure 8 shows the in vivo safety assessment, indicating no significant pathological abnormalities in major organs or body weight changes across different treatment groups.